loader2
Partner With Us NRI

Syncom Formulations (India) Ltd share Price Today

Company details

13.35
13.80
6.25
18.65
6M Return 29.47%
1Y Return 103.03%
Mkt Cap.(Cr) 1,259.60
Volume 2,216,056
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 2,216,056

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Syncom Formulations (India) Ltd shares SWOT Analysis

Strengths (9)

  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Company with Low Debt
  • Increasing Revenue every quarter for the past 3 quarters

Weakness (0)

Data not found

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (2)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 13.9
R2 14.2
R3 14.5
Pivot

13.55

S1 13.3
S2 12.9
S3 12.6
EMA SMA
13.4
13.4
13.2
12.1
13.6
13.0
14.2
11.9
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-12-27 15.78 7392090 NSE
QE SECURITIES LLP Bulk Purchase 2023-12-27 15.93 5098247 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2023-12-27 15.82 7527340 NSE
Name Category Shares
KEDARMAL SHANKARLAL BANKDA PROMOTER 12.44%
VIJAY SHANKARLAL BANKDA PROMOTER 10.48%
ANKIT BANKDA PROMOTER 4.99%
ASHA VIJAY BANKDA PROMOTER 4.9%
VIMLA BANKDA PROMOTER 4.26%
VIJAY BANKDA HUF PROMOTER 1.28%
PAYAL ANKUR BANKDA PROMOTER 1.25%
KEDARMAL SHANKARLAL BANKDA HUF PROMOTER 1.12%
SULABH RAHUL BANKDA PROMOTER 0.99%
PARADISE VYAPAR PRIVATE LIMITED PROMOTER 5.02%
STRAND DEVELOPERS PVT. LTD. PROMOTER 3.82%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Syncom Formulations (India) Ltd Stocks COMPARISON

Financials( in Cr) Syncom Formulations (India) Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 13.40 1,531.40 1,399.05 1,051.40 3,910.75
% Change -1.47 0.26 -0.54 5.45 0.47
Mcap Cr 1,259.60 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 224.25 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 20.07 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 48.50 39.15 26.62 28.83 75.36
1 Year Return 103.03 60.69 51.61 103.07 19.36
ROCE 9.57 16.79 14.76 16.25 19.30
ROE 8.39 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 256.01 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 44,248.95 -31,659.16
LAST 3M 105,886.10 -43,482.14
LAST 6M 173,149.22 48,654.40
LAST 12M 264,707.07 127,969.33
NSE Board Meetings Forthcomming

May 17, 2024 l NSE Board Meetings Forthcomming

Board Meeting for Today

May 17, 2024 l Board Meetings for Today

Syncom Formulations (India) Limited - Disclosure under SEBI Takeover Regulations

May 15, 2024 l NSE Announcement

Date Action Type Ratio
Sep 09, 2022 Dividend 3

Syncom Formulations (India) Ltd Information

Stock PE (TTM)
48.5
Promoter Holding
50.57%
Book Value
2.8742
ROCE
9.57%
ROE
8.39%
Description
  • Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.`92. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.`89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.`94 was completed in 1995. During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%. During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt. The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department by putting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installed capacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of the capacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulation sections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003. In 2007, the Company launched a new division "Cratus Life Care" to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008. In 2020-21, the business activity of the Company was expanded by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum and to modernize the Tablet Department within an overall cost of Rs. 4031.50 Lakhs which was funded by the issuance of fresh share capital to meet the overall cost of the project.

Registered Address

7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd, Mumbai, Maharashtra, 400093

Tel : 91-22-30887744
Email : finance:sfil.in; sfil87:syncomformulations.com
Website : http://www.syncomformulations.com
Registrar

Ankit Consultancy Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524470
NSE Code : SYNCOMF
Book Closure Date (Month) : Sep
BSE Group : T
ISIN : INE312C01025

FAQ’s on Syncom Formulations (India) Ltd Shares

You can buy Syncom Formulations (India) Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Syncom Formulations (India) Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:59 PM the closing price of Syncom Formulations (India) Ltd was Rs.13.40.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:59 PM, the market cap of Syncom Formulations (India) Ltd stood at Rs. 1,259.60.

The latest PE ratio of Syncom Formulations (India) Ltd as of May 17, 2024 03:59 PM is 48.50

The latest PB ratio of Syncom Formulations (India) Ltd as of May 17, 2024 03:59 PM is 0.21

The 52-week high of Syncom Formulations (India) Ltd share price is Rs. 18.65 while the 52-week low is Rs. 6.25

Download App

Download Our App

Play Store App Store
market app